Bioinformatic analysis

Discover how severely COVID-19 could affect you – using your DNA data. Our research-based tool can analyze your genetic factors in less than 1 minute!
Just upload a raw data file* from your chosen DNA provider – including 23andMeAncestryGenotekMyHeritage and many others.
Get your free report now:

*We accept uncompressed DNA data in txt, csv and vcf formats. Please follow the instructions from official pages to download your raw data: 23andMe, AncestryDNA, Genotek, MyHeritage. Click here to view a sample of our report.

BCRPO.APP offers neither diagnostic services nor monitoring or treatment of diseases. This app does not replace medical advice or treatment. The results available in the BCPRO.APP report are for informational and educational purposes only and may not under any circumstances be interpreted or treated as advice or a consultation or a diagnosis of a medical doctor.

If this is an emergency, call your local emergency number immediately. Do not proceed with the BCPRO.APP. Medical attention is required immediately.

We are developing novel methods of analyzing genetic data to produce actionable insights on human health.

Our Approach


The main human histocompatibility complex is commonly called HLA (human leukocyte antigen). There are three types of HLA class I molecules: HLA-A, HLA-B, and HLA-C. Every human inherits two separate copies of every type, each – with several specific mutations. A set of six HLA molecules participates in the formation of CD8+ T-cell immunity, presenting small pieces of viral proteins (peptides) on the surface of infected cells. CD8+ T cells are then programmed to kill infected cells by recognizing and memorizing the presented peptides. The earlier and more actively this phase occurs, the faster and more efficiently the human immune system will defeat the disease.

The main catch is that different sets of HLA molecules have different ability to recognize and present peptides of the SARS-CoV-2 virus: with successful mutations in HLA molecules, more efficient binding of peptides is possible, while "bad" mutation slows down this process. We have developed an algorithm that can estimate whether the set of HLA molecules is "good" for fighting COVID-19, or vice versa. Our model was successfully validated on 100+ patients with severe case of COVID-19 and a control group of 400+ people.

The results of our research are published in Frontiers in Immunology.